Every material Form 8-K Onconetix, Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Onconetix, Inc. said its Board approved an additional one-for-ten reverse stock split of its common stock, which will bring the aggregate split ratio under the stockholder-approved authority to one-for-one hundred with a May 21, 2026 split. Shares are expected to begin trading on a split-adjusted basis on Nasdaq on November 6, 2026, under the existing symbol ONCO. The split reduces the share count but does not change any stockholder's percentage ownership, apart from cash paid for fractional shares.
Reverse split of one-for-ten is expected to take effect at 12:01 a.m. Eastern Time on November 6, 2026
Outstanding shares expected to fall from approximately 5.9 million to approximately 589,000
Combined with the May 21, 2026 split, the aggregate ratio is one-for-one hundred; new CUSIP 68237Q500 and symbol ONCO unchanged
No fractional shares will be issued; holders will receive cash in lieu, and authorized shares remain at 250,000,000
Onconetix made an additional $500,000 advance to its subsidiary Realbotix, LLC on October 22, 2026, under a Grid Promissory Note dated September 11, 2026. Outstanding principal under the note is now $3.0 million of a up to $5.0 million facility, and the note's terms are unchanged.
Additional advance of $500,000 made October 22, 2026 to Realbotix, LLC
Aggregate principal outstanding under the Grid Promissory Note is $3.0 million
Total facility allows loans of up to $5.0 million; $2.5 million was advanced on September 11, 2026
Terms of the note remain unchanged from the September 14, 2026 Form 8-K disclosure
Onconetix agreed on September 11, 2026 to lend up to $5.0 million to Realbotix, LLC, the target of its pending all-stock acquisition, with $2.5 million advanced at signing. The loan is non-interest bearing until the acquisition closes or is terminated, and the balance is cancelled at closing, which reduces the cash Onconetix must hold at closing. For shareholders, the filing shows the financing terms but no change to the acquisition's status, which still requires Onconetix shareholder and regulatory approvals.
Loan of up to $5.0 million to Realbotix, with $2.5 million advanced on September 11, 2026; note matures September 11, 2027
Note is non-interest bearing until the Share Exchange Agreement closes or terminates; 12% annual interest accrues if terminated
At closing, the note is cancelled and the required Net Cash at Closing rises by $500,000 plus the outstanding principal
Realbotix Corp. guarantees the note; closing requires at least $12.5 million in Net Cash
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Onconetix, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →